Metanálise de estudos randomizados | Agonistas receptores de GLP1 aumentam o risco de doenças de vias biliares e vesícula biliar (RR 1,37; IC 95%, 1,23-1,52).

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials – JAMA Internal Medicine (gratuito por tempo limitado)

Commentary: GLP-1 Receptor Agonists: How Safe Are They for the Gallbladder?— Link with gallbladder, biliary diseases could be due to weight loss associated with class of drug – MedPage Today (gratuito por tempo limitado)